Cetera Investment Advisers Purchases 989 Shares of Thermo Fisher Scientific Inc. $TMO

Cetera Investment Advisers increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 66,807 shares of the medical research company’s stock after acquiring an additional 989 shares during the period. Cetera Investment Advisers’ holdings in Thermo Fisher Scientific were worth $27,087,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC raised its holdings in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at approximately $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at $31,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific in the first quarter worth $35,000. Finally, DiNuzzo Private Wealth Inc. increased its holdings in Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 61 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMO has been the topic of a number of analyst reports. Robert W. Baird upped their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Argus lifted their target price on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Nineteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Thermo Fisher Scientific Price Performance

TMO stock opened at $567.49 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company’s 50-day moving average is $529.51 and its 200-day moving average is $469.36. The stock has a market capitalization of $213.21 billion, a PE ratio of 32.78, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the prior year, the business earned $5.28 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock buyback plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Activity

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 10,225 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $571.62, for a total value of $5,844,814.50. Following the transaction, the vice president directly owned 14,145 shares of the company’s stock, valued at approximately $8,085,564.90. This trade represents a 41.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $574.15, for a total transaction of $229,660.00. Following the sale, the executive vice president directly owned 21,152 shares of the company’s stock, valued at approximately $12,144,420.80. The trade was a 1.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 52,140 shares of company stock valued at $29,104,464. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.